Survey Reveals Better Care Needed for Hospitalized Patients with Diabetes
WALTHAM, Mass.--(BUSINESS WIRE)--Nov 5, 2019--
According to a recent survey, more than 75% of U.S. hospitals employ an outdated form of insulin therapy inconsistent with recommendations by the American Diabetes Association, American Association of Clinical Endocrinologists, Society of Hospital Medicine and other authoritative sources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005113/en/
Results of a nationwide survey indicate many of the processes and protocols fundamental to high-reliability care for patients with diabetes are absent or lacking in our nation’s hospitals, with more than 75% using an outdated form of insulin therapy inconsistent with recommendations by the American Diabetes Association, American Association of Clinical Endocrinologists, Society of Hospital Medicine and other authoritative sources. (Graphic: Business Wire)
On average, one of every three hospitalized patients -- the majority with diabetes -- requires insulin to control blood glucose during their stay. Although widely prescribed and absolutely necessary, insulin is inherently dangerous: 50% of all medication errors involve insulin, including one-third of all fatal medication errors. Results of the survey indicate many of the processes and protocols fundamental to high-reliability care for patients with diabetes are absent or lacking in our nation’s hospitals.
Download the complete survey results here.
When best practices for insulin therapy are not the norm and variation is widespread, poorly controlled blood glucose prevails, which can lead to coma, stroke, sepsis, cardiac arrest… even death. A recent study by AdventHealth Orlando showed that hospitalized patients who experience severe hypoglycemia (abnormally low blood glucose) incur $10,405 of excess cost, a 61.5% higher readmission rate and a 6.6-day longer stay. With the shift from volume to value, diabetes care and glycemic management must become strategic imperatives.
Among a total of 619 survey respondents representing 408 U.S. hospitals:
The good news is, improving the care of hospitalized patients with diabetes and achieving best practices in glycemic management are attainable goals, especially with the aid of purpose-built technologies such as the eGlycemic Management System ® from Glytec.
Healthcare professionals and leaders may arrange a complimentary consultation with a Glytec physician executive to discuss their glycemic goals, needs and challenges. Click here to schedule time at the upcoming Becker’s CEO + CFO Roundtable, IHI National Forum or by phone.
Founded in 2006, Glytec is the pioneer of digital therapeutics, improving lives of people with diabetes through insulin optimization technologies and services. The company’s patented eGlycemic Management System ® is the only FDA-cleared software-as-a-medical-device (SaMD) platform purpose built to support best practices in insulin therapy across the continuum of care: inpatient, outpatient and virtual settings alike. Glytec offers several comprehensive programs combining evidence-based decision support technologies with expert professional services proven to reduce hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191105005113/en/
Joy Efron, 864-263-4160
Vice President Marketing
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: TECHNOLOGY BIOTECHNOLOGY DIABETES HEALTH OTHER HEALTH PHARMACEUTICAL PRACTICE MANAGEMENT MEDICAL DEVICES SOFTWARE MANAGED CARE HOSPITALS CLINICAL TRIALS NURSING MEDICAL SUPPLIES
Copyright Business Wire 2019.
PUB: 11/05/2019 08:00 AM/DISC: 11/05/2019 08:01 AM